Sublingual immunotherapy (SLIT) is effective against allergic rhinitis, although a substantial proportion of individuals is refractory. Herein, we describe a predictive modality to reliably identify SLIT non-responders (NRs). We conducted a 2-year clinical study in 193 adult patients with Japanese cedar pollinosis, with biweekly administration of 2000 Japanese allergy units of cedar pollen extract as the maintenance dose. After identifying high-responder (HR) patients with improved severity scores and NR patients with unchanged or exacerbated symptoms, differences in 33 HR and 34 NR patients were evaluated in terms of peripheral blood cellular profiles by flow cytometry and serum factors by ELISA and cytokine bead array, both pre-and post-SLIT. Improved clinical responses were seen in 72% of the treated patients. Pre-therapy IL-12p70 and post-therapy IgG1 serum levels were significantly different between HR and NR patients, although these parameters alone failed to distinguish NR from HR patients. However, the analysis of serum parameters in the pre-therapy samples with the Adaptive Boosting (AdaBoost) algorithm distinguished NR patients with high probability within the training data set. Cluster analysis revealed a positive correlation between serum T h 1/T h 2 cytokines and other cytokines/chemokines in HR patients after SLIT. Thus, processing of pre-therapy serum parameters with AdaBoost and cluster analysis can be reliably used to develop a prediction method for HR/NR patients.
Introduction
Allergen-specific immunotherapy (AIT) effectively treats allergic diseases (1) (2) (3) . Recently, the application of sublingual immunotherapy (SLIT), rather than classical subcutaneous immunotherapy (SCIT), has expanded owing to its equivalent efficacy and reduced side effects. SLIT significantly improved severity scores and lowered the use of symptomatic anti-allergy drugs in allergic rhinitis (AR) patients, as demonstrated by several meta-analyses from >60 doubleblind, placebo-controlled clinical trials (3, 4) .
Despite its high efficacy, a substantial proportion of patients is refractory to AIT (5, 6) . Although 50-70% of patients with AR or bronchial asthma respond favorably to SCIT or SLIT, these therapies are ineffective for the remaining ~30% (5, 6) . Although the mechanisms of AIT in mitigating allergic reactions have been well studied (7) (8) (9) (10) , the reason for the large proportion of unaffected patients remains unclear. Treating patients who do not respond to AIT is futile and should be avoided. Therefore, it is desirable to identify and exclude nonresponder (NR) patients before initiating AIT; however, no predictive biomarkers or diagnostic tests have been developed (8) , at least partially, because the pathophysiological and genetic differences between AIT-responder and NR patients are ambiguous. In addition, as is often the case when searching for biomarkers mediating the development and severity of allergic diseases (11, 12) , it is difficult to identify a single biomarker that comprehensively predicts the efficacy of SLIT because of the complicated pathogenesis involved.
In comparison with the first worldwide research on the prevalence of AR performed in 1998 (13) , recent epidemiological studies clearly demonstrate that the number of patients receiving AR has been continuously increasing (14) (15) (16) (17) . In parallel, an upsurge of patients with Japanese cedar polleninduced AR (JCPAR) has occurred in Japan (18) . JCPAR is a typical seasonal allergy lasting ~3 months from February to April, during which time widely dispersed airborne cedar pollen causes AR and/or conjunctivitis in ~25% of the Japanese population (19) . SLIT with cedar pollen extract was recently approved to treat JCPAR (20) . Although clinical results indicate that SLIT is highly efficacious against JCPAR, NRs also exist (21) (22) (23) .
Therefore, to identify differences between the responder and NR patients, particularly before AIT initiation, we performed a clinical study of patients with JCPAR receiving SLIT. We comprehensively analyzed cellular and serum parameters by using a novel ensemble-learning algorithm to identify biomarkers capable of discerning high-responder (HR) and NR patients before SLIT initiation.
Methods

Subjects
Patients with JCPAR who were residents of Tokyo, Japan, who were over 20 years old and who were attending Nippon Medical School Hospital, Tokyo Metropolitan Hospitals, and clinics in Tokyo from May to June 2006 were included. All patients showed AR symptoms, such as sneezing, rhinorrhea and nasal congestion, from February to April (pollen season) for at least three consecutive years before undergoing SLIT. They were positive in skin-prick tests and for IgE against cedar pollen allergen. Patients were excluded based on the following criteria: (i) positive for Japanese cypress pollen-specific IgE, (ii) complicated symptoms with other nasal diseases, (iii) use of drugs affecting SLIT efficacy such as anti-allergic drugs and steroids, (iv) history of bronchial asthma or urticaria at age 15 or older, (v) previous treatment with SCIT, (vi) pregnancy or potential pregnancy, (vii) lactation and (viii) recommended exclusion by attending physicians owing to complications such as liver, kidney or heart disease, respiratory infection, or other severe disorders.
Allergen administration
For the sake of this study, standardized cedar pollen allergen purchased from Torii Pharmaceutical Co., Ltd (Tokyo, Japan) was self-administered at home, as described previously (22) . Briefly, patients held the allergen solution under the tongue for 2 min and then spat it out. The self-administered allergen was gradually increased over 5 weeks from one drop containing 2 Japanese allergy units (JAU) ml −1 to up to 20 drops of 2000 JAU ml −1 as the maintenance dose by 5 weeks (Table  1) , beginning in July (first year, Fig. 1 ) and continuing for 2 years. The standard of care treatment and other treatments to control allergic symptoms were not performed, except that a single use of oral and ophthalmic anti-histamines was permitted for severely exacerbated patients. These treatments were not expected to significantly affect pre-and post-SLIT parameters because the evaluation occurred after the pollen season ended.
HR and NR patient classification
Nasal symptoms recorded by the patients from February 1 to April 30 during three pollen seasons (first to fourth year) were investigated using the Japanese guidelines for AR as described previously (18, 24) . Briefly, the numbers of sneezing and nose-blowing episodes, extent of nasal congestion and eye itchiness, symptom duration and medication compliance were self-recorded daily using an allergy diary, according to the classification scheme developed by Okuda et al. (25, 26) . The quality of life of the patients was determined three times at the end of February, mid-March and mid-April each year using the Japanese Rhinoconjunctivitis Quality of Life Questionnaire No. 1 (JRQLQ1). At the end of each pollen season, SLIT efficacy was evaluated by comparing the patients' five-grade severity scores (most severe, severe, moderate, mild or asymptomatic), as determined by the allergy diary and the JRQLQ1 in each year to that before the start of SLIT as reported previously (25, 26) . After SLIT, the top 33 HR patients showing more than one-step improvement in severity score and the bottom 34 NR patients with unchanged or exacerbated conditions were selected. For all patients matching the above criteria, peripheral blood and The number of drops of allergen solution administered to subjects at each time point is indicated. a Biweekly.
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Cell preparation
PBMCs were prepared by Ficoll-Paque density-gradient centrifugation, as described previously (27) . Then, B cell and macrophage/monocyte fractions were removed using a magnetic cell-sorting system (AutoMACS, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) with anti-CD14-biotin 
Serum mediator analysis
Cedar pollen-and cypress pollen-specific and total IgE were measured using ImmunoCAP Specific IgE and ImmunoCAP Total IgE kits, respectively (Thermo Fischer Scientific Inc., Uppsala, Sweden). Cedar pollen-specific IgG1-4 was measured by ELISA using Cedar Pollen Crude Extract-Cj (Cosmo Bio, Tokyo, Japan) as the capture protein and HRPconjugated mouse anti-human IgG1-4 (Southern Biotech, Birmingham, AL, USA) as the detecting antibody.
In , where v is a subject's raw data, μ is the mean value observed in the population and σ is the associated standard deviation in the population. Using Pearson's product-moment correlation coefficients for the profiles of cytokine levels in pre-treatment HRs, the data were hierarchically clustered by the unweighted pair-group method with the arithmetic mean (UPGMA). By isolating the dendrogram branches at a correlation coefficient of 0.7, cytokine clusters mutually correlated in HRs were identified.
Adaptive boosting analysis
Adaptive boosting (AdaBoost) is an ensemble-learning algorithm for predicting the attribution of unknown subjects by referring to previously analyzed data (28) . To identify factors predicting HR or NR phenotypes, serum cytokine levels were analyzed using AdaBoost. We generated the best additional weak learner (a decision stump) in each incremental step by exhaustively searching for the best explanatory attribute T t , with its threshold v t and the directions of inequalities. AdaBoost determines the weight for the majority decision, wt. Letting f t (x) and w t , respectively, denote the result of the tth weak learner for subject x and the weight for the majority decision, a strong learner is constructed using the weighted linear summation of all results from weak learners, F(x) = Σ(w t × f t (x)). When the resulting F(x) is >0 or <0, subject x is predicted as NR or HR, respectively. The value of f t (x) is +1 or −1. The weights for the majority decision, w t , were determined as follows. Suppose the total number of the subjects was N and each subject, x, had its weight in the t-th incremental step, D t (x), with the equal initial weight, D 1 (x) = 1/N. All candidate weak learners could have prediction accuracy >50% (if not, the prediction results would be inverted). The algorithm evaluated the weighted error rate, ε t , by summing D t (x) for which a candidate weak learner made a wrong prediction, i.e. ε t = ΣD t (x). The candidate who achieved the minimum weighted error rate was adopted as the t-th weak learner. The weight of the weak learner was defined by w t = 0.5ln{(1 − ε t )/ε t }. The algorithm then updated the weights of the subjects;
) and y(x) was the true value (+1 or −1), indicating whether the subject x was NR or HR. The same analysis was performed to distinguish NR and mid-range patients. Prediction accuracy was assessed as the percentage of correct predictions.
Statistical analysis
Severity scores, cell populations, serum factors and cluster analysis are expressed as the mean ± SEM. Data for clustering and AdaBoost are presented in heat map images. Statistical analysis for paired and unpaired comparisons was performed by Wilcoxon signed-rank testing and MannWhitney U-testing, respectively.
Study approval
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All experi- 
Results
SLIT efficacy
Nine of 202 patients did not meet the inclusion criteria or declined allergen administration. Twenty patients (10.4%) withdrew during the first year, 17 (8.8%) during the second year and 51 (26.4%) total. Eight patients (4%) withdrew because of mild side effects such as skin and oral itching, eruption, nasal discharge and obstruction, sneezing, swollen eyes and headaches. No severe side effects were observed.
Following cedar pollen allergen administration for 2 years ( Fig. 1 and Table 1 ), the severity scores were improved (Fig. 2A) . The proportion of patients with the most severe symptoms dramatically decreased from 31% (first year) to 4% (third year), and the proportion of asymptomatic patients increased from 5 to 29%. Compared to the baseline (first year), the number of patients with more than one-step improvement in severity score increased from 52% in the second year to 72% in the third year (Fig. 2B) . SLIT effectiveness lasted ≥1 year after ceasing allergen administration. Most importantly, and consistent with previous investigations (5, 6), ~30% of patients failed to show improvement after 2 years. The top 33 HRs (aged 39.3 ± 11.0 years, male:female = 8:17) and the bottom 34 NRs (aged 47.8 ± 12.1 years, male:female = 11:14) were selected (Fig. 2C) . No significant pre-treatment differences in clinical scores were observed between the HRs (3.94 ± 0.98) and NRs (3.12 ± 0.98). In both groups, > 95% patients received SLIT by following the exact allergen administration schedule. Severe exacerbation was not observed in HR patients.
As determined by Durham's method (29) , the airborne cedar pollen count in Chiyoda-ku, Tokyo, Japan during the first 2 years was lower than the average of the last 10 years, whereas that during the last 2 years was comparable to this average (http://www.tokyo-eiken.go.jp/kj_kankyo/kafun/data_ spring/; Supplementary Figure S2 , available at International Immunology Online).
Cell population analyses
CD4
+ T cells and cDCs, which are involved in antigen recognition and presentation, respectively, are implicated in AIT pathogenesis (7) (8) (9) (10) 30) . Basophil and pDC involvement in allergic diseases was also shown recently (31, 32) . We analyzed these cell types to investigate the mechanisms . Changes in severity scores in HR and NR patients from the first to third year were calculated and expressed as the mean ± SEM with individual data (C). **P < 0.01, ***P < 0.001 (n = 33-34, Mann-Whitney's U-test). Figure S1 , available at International Immunology Online). In addition to equivalent pre-treatment levels of CD4 + T cells, basophils, cDCs and pDCs in CD14/ CD16/CD19 cell-depleted PBMCs in HR and NR patients, these populations were unaffected by SLIT (Fig. 3) , indicating that SLIT efficacy was not mediated by differences in the frequency of CD4, basophil, cDC and pDC immune subsets.
of SLIT (Supplementary
Serum immunoglobulin and cytokine analysis
Serum immunoglobulin levels in the HR and NR groups were essentially equal before the study (Fig. 4A and B) . SLIT significantly increased allergen-specific IgE and the allergenspecific/total IgE ratio in both groups. Total IgE levels and allergen-specific IgG subtypes were elevated only in the NR group (Fig. 4A and B) . Serum levels of several cytokines were significantly changed following SLIT (Supplementary Figure S3 , available at International Immunology Online); only IL-12p70 and IgG1 levels were significantly different between HR and NR patients before and after SLIT, respectively ( Fig. 4B and C) .
Serum factor analysis with AdaBoost
Although the differences in IL-12p70 and IgG1 levels were significant, the HR and NR groups could not be distinguished based on these parameters alone. Therefore, all cytokine data measured in pre-treatment sera were processed with AdaBoost (28) . From the first weak learner, IL-12p70, with an accuracy of 0.57, the accuracy improved as weak learners were added, finally reaching 0.97 using 24/50 categories of cytokines measured (Fig. 5A) . Of 94 total mid-range patients, 51 not selected as HR or NR were subsequently categorized as NR by the AdaBoost learners generated using the HR plus NR training data set. Therefore, an additional AdaBoost analysis was performed for the resulting NR plus mid-range patients. From the first weak learner, TRAIL, NR and midrange patients were divided with an accuracy of 0.70, which ultimately reached 0.95 when using 25 cytokine categories (Fig 5B) . These findings suggest the usefulness of this strategy for constructing strong learners that enable identification of NR patients before SLIT with high probability by collecting serum cytokine data from many patients.
Clustering analysis of serum factors
To obtain the basal cytokine profile of HR patients, serum cytokine data were hierarchically clustered according to their profiles in the pre-treatment HR group. We found that the correlations in six groups of serum factors-namely TRAIL, SDF-1α, M-CSF, β-NGF, IL-2Rα and MIF; IL-12p40, IL-1α, TNF-β and LIF; FGFbasic and IL-8; IFN-γ, IL-4, G-CSF, IL-10, IL-5, TNF-α, IL-13, IL-7, MCP-1, IL-15, IL-6, IL-2, IL-1Rα, IL-1β and eotaxin; IFN-α2, IL-16, MCP-3 and IL-3; and GM-CSF and IL-12p70-were clearly different between the HR and NR groups (Fig. 6A) . Particularly, a strong correlation was observed among typical T h 1 cytokines such as IFN-γ, TNF-α and IL-1β, as well as T h 2 cytokines such as IL-4, IL-5 and IL-13 in the HR group (Figs. 6A and E) . The average correlation coefficients in this IFN-γ/IL-4/G-CSF/IL-10/IL-5/TNF-α/ IL-13/IL-7/MCP-1/IL-15/IL-6/IL-2/IL-1Rα/IL-1β/eotaxin cluster were significantly different between HR and NR groups both before and after SLIT. The significant difference between the HR and NR groups was also seen in the relationships in the TRAIL/SDF-1α/M-CSF/β-NGF/IL-2Rα/MIF cluster (Fig. 6B) . The level of correlation in the former cluster in HR patients was decreased in response to SLIT, whereas that in the later cluster in NR patients was increased. The relationships in the FGFbasic/IL-8 (Fig. 6D) and GM-CSF/IL-12p70 (Fig. 6G) clusters were much weaker in the NR group.
Discussion
The data presented herein demonstrate that HR and NR JCPAR patients can be distinguished before the initiation of SLIT based on serum cytokine levels, suggesting a possible predictive means for SLIT efficacy.
It is obviously useful to identify NR patients to be excluded from SLIT, which must be continued for several years once it is begun, although few studies have addressed the issue of pre-therapy identification of potential NRs. Di Lorenzo et al. demonstrated a significant correlation between the serum allergen-specific/total IgE ratio and clinical responses to SLIT and SCIT (5); higher AIT efficacy was achieved for rhinitis patients showing higher serum allergen-specific/total IgE ratios, and HR and NR patients could be predicted from this ratio with 77.8-100% accuracy (5), as observed in another SLIT trial (23) . These findings are impressive because relatively high predictive values were obtained using a single parameter (5). However, this pattern was not reproducible here. Although cedar pollen-specific/total IgE ratios were significantly increased by SLIT, these increases were largely equivalent in the HR and NR groups of our study cohort. The reason for the discrepancy is unclear, and further studies involving detailed time courses and longer follow-up are required to validate the usefulness of such parameters in predicting AIT efficacy unequivocally.
Only pre-treatment IL-12p70 and post-treatment IgG1 levels were significantly different between HR and NR in serum analyses. Increased serum IgG1 level is a characteristic of AIT-treated patients (8) and has been associated with IgGmediated serum inhibitory activity for allergen-IgE binding to B cells (33) , indicating that IgG1 is involved in AIT pathophysiology. However, this was contradicted in the present study, in which a significant increase in IgG1 was seen only in posttreatment NR patients. Further investigation will be required to confirm whether IgG1 facilitates SLIT resistance.
In addition, the significant increase of IL-12p70 levels in NR patients appears consistent with previous reports demonstrating the elevation of nasal IL-12 as well as other T h 1 cytokines following AIT (34, 35) . However, the serum IL-12p70 level in HR patients was already high before treatment and was dramatically reduced by SLIT. As such, T h 1 and T h 2 cytokines might be co-regulated in HR patients but not in NR patients. This T h 1/T h 2 theory is widely recognized in the field of allergy (36, 37) , and the shift of T h 2 CD4
+ T cells to T h 1 cells by AIT is known (7, 8) . Nevertheless, our findings on serum immunoglobulin levels were inconsistent with the T h 1/T h 2 theory. For instance, pre-treatment IL-12p70 was higher in HR, whereas T h 1-related IgG2 and IgG4 were equivalent in HR and NR. In contrast, T h 2-related IgG1 was HR/NR patients are distinguishable before SLIT 295 higher in post-treatment HR, although the difference in IgE levels was not clear. While the precise reasons for these discrepancies remain unclear, the timescale of cytokine and immunoglobulin production was different: cytokine synthesis is regulated within hours or days, whereas immunoglobulins are produced over the course of weeks or months. Thus, 4 . Effects of SLIT on serum factors. Total and pollen-specific IgE, specific/total IgE ratio (A), pollen-specific IgG subclasses (B) and IL-12p70 (C) in the sera of HR and NR patients were measured as described in the Methods section and expressed as the mean ± SEM (n = 25-34). *P < 0.05, **P < 0.01, ***P < 0.001 (Wilcoxon signed-rank test); # P < 0.05,
the differences in cytokine levels-such as pre-treatment IL-12p70-might reflect immunoglobulin levels at a later time point. Since IgE switching occurs directly or via IgG (38), higher post-treatment IgG1 in HR might induce the elevation of IgE after the study end-point. As such, a longer and more frequent evaluation of serum parameters is required to clarify the detailed relationship between serum cytokines and immunoglobulins in patients receiving SLIT. Furthermore, the complex contribution of T cells to allergic disease pathogenesis is being increasingly recognized. Cytokines synthesized by several new T-cell subsets, such as T h 9, T h 17, T h 22 and Treg cells, can play different roles (39, 40) . More severe and chronic disease conditions are associated with the presence of a wider variety of T-cell subsets (41, 42) . The suppressive function of Treg cells against T h cells shows some selectivity (43) , and some T h cells promote Treg cell function (44) . These complications in allergic inflammation might affect the responsiveness of patients receiving T-cell-targeted therapies, including AIT. Collectively, the poles separating HR and NR patients in our clustering analysis indicated that the high T h 1/T h 2 correlation in HR patients might be pivotal in their responses to SLIT. Since we did not observe differences in the frequency of CD4 + T cells, basophils, cDCs and pDCs between HR and NR patients, it may be necessary to evaluate the individual cell subsets and/or their activation status. Wachholz et al. demonstrated that the effect of AIT was related to T h 1/T h 2 cytokine levels in nasal tissues, but not in serum (34) . Therefore, further investigation of nasal parameters might provide additional information useful in predicting SLIT effectiveness.
Intriguingly, SLIT-naive HR and NR patients were distinguishable by serum cytokine profiles in our training data set. AdaBoost differs from a bootstrap aggregating algorithm that randomly generates equally weighted weak learners independently (45) . Because AdaBoost was confirmed to be a robust and reliable method for decision making (46) , it has been applied for many classification tasks, for example in image processing related to various diseases (47) (48) (49) . Because AdaBoost incrementally and iteratively generates variously weighted weak learners, an additional weak learner in each round of iteration enables focused examination of subjects that have been falsely predicted by the previously generated weak learners. The threshold values in the new weak learner were determined by exhaustive searching. The resulting strong learner is optimized to predict values of the objective attribution in the training dataset (28) . High prediction accuracy was achieved by this optimization strategy, which was originally implemented for this study. Substantial predictability was obtained by using only the training data set herein, and two-round selection steps were needed to extract NR from HR plus mid-range patients. Therefore, additional analyses of larger cohorts are required to unequivocally establish and validate the robustness of our approach in identifying patients most likely to benefit from SLIT.
In conclusion, we demonstrated a predictive modality for SLIT responsiveness in AR patients by employing AdaBoost. Figure S3 (available at International Immunology Online) along with those of mid-range patients were processed with AdaBoost. Each row in the left-hand panel shows a weak learner represented by a combination of the name of an explanatory attribution; Tt, its threshold; vt, the direction of inequality and wt, the weight for the majority decision. Each column in the right-hand panel corresponds to a subject. The top rows of the columns represent the true classification of the subjects, where the red, blue and green cells represent NR, HR and mid-range patients, respectively. Each row in those columns shows the prediction results, F(x), for the strong learner generated in each iteration round by AdaBoost. In the t-th row, the strong learner was constructed using the first t of weak learners, and the red and blue cells respectively show whether the value of F(x) is positive (predicted as NR) and negative (predicted as HR) (A). The resulting positive NR and mid-range patients predicted as NR by the first-round AdaBoost were further processed with a second-round AdaBoost (B). The red and green cells indicate whether the value of F(x) was positive (predicted as NR) or negative (predicted as mid-range), respectively. The numbers in the right column show the cumulative accuracy, P 1~t , attained using the first to the t-th weak learner. 
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The clustering analysis revealed that differences in the relationships among cytokines may be involved in the mechanisms underlying SLIT efficacy. Further examination of larger cohorts with additional analytical parameters-such as gene expression and polymorphism-would expand our understanding of the immunological mechanisms of SLIT in AR.
Supplementary data
Supplementary data are available at International Immunology Online.
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